Drug Landscape ›
Duloxetine 60mg ›
Regulatory · United States
Marketing authorisations
FDA — authorised 3 August 2004
Application: NDA021427
Marketing authorisation holder: LILLY
Local brand name: CYMBALTA
Indication: CAPSULE, DELAYED REL PELLETS — ORAL
Status: approved
Read official source →
FDA — authorised 3 September 2004
Application: NDA021733
Marketing authorisation holder: LILLY
Local brand name: CYMBALTA
Indication: CAPSULE, DELAYED REL PELLETS — ORAL
Status: approved
Read official source →
FDA — authorised 13 June 2008
Application: NDA022148
Marketing authorisation holder: LILLY
Local brand name: CYMBALTA
Indication: CAPSULE, DELAYED REL PELLETS — ORAL
Status: approved
Read official source →
FDA — authorised 4 November 2010
Application: NDA022516
Marketing authorisation holder: LILLY
Local brand name: CYMBALTA
Indication: CAPSULE, DELAYED REL PELLETS — ORAL
Status: approved
Read official source →
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 122
Most-reported reactions
Product Substitution Issue — 24 reports (19.67%) Depression — 19 reports (15.57%) Dizziness — 16 reports (13.11%) Anxiety — 12 reports (9.84%) Headache — 12 reports (9.84%) Nausea — 11 reports (9.02%) Suicidal Ideation — 8 reports (6.56%) Insomnia — 7 reports (5.74%) Product Quality Issue — 7 reports (5.74%) Diarrhoea — 6 reports (4.92%)
Source database →
Duloxetine 60mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Duloxetine 60mg approved in United States?
Yes. FDA authorised it on 3 August 2004; FDA authorised it on 3 September 2004; FDA authorised it on 13 June 2008.
Who is the marketing authorisation holder for Duloxetine 60mg in United States?
LILLY holds the US marketing authorisation.